Gracell Biotechnologies PIPE of ordinary shares and warrants
The company’s ADSs are listed on Nasdaq
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
BMS $35 million investment in Immatics
We advised Immatics on the private placement of ordinary shares
Korro Bio $117 million private placement
The financing is expected to close immediately prior to the completion of Korro Bio’s merger with Frequency Therapeutics
Samarco Mineração enters into restructuring support agreement
We are advising an ad hoc group in connection with the restructuring
XPO $1.28 billion senior notes offerings
The senior notes are due 2028 and 2031
Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
InflaRx follow-on offering
The shares are listed on the Nasdaq Global Market
Ormat Technologies $297 million follow-on offering
The stock is listed on the NYSE and Tel Aviv Stock Exchange
Alteryx $450 million senior notes offering
The 8.75% notes are due 2028